Russia again faced with drug shortages

31 August 2021

Russia again faces a shortage of foreign drugs for the treatment of serious diseases, this time for the treatment arthritis, according to recent statements by representatives of local patent associations and some local media, reports The Pharma Letter’s local correspondent.

Currently probably the most complex situation is observed in case of methotrexate solution which was included by the government in the list of vital and essential drugs (VED) being constantly taken by 2-2.5 million people in the country.

At present Methotrexat-Ebewe injection solution is supplied by the Swiss company Sandoz (a Novartis [NOVN: VX] group subsidiary), which is the largest supplier of methotrexate to the Russian market.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK